Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin.
about
What you always needed to know about electroporation based DNA vaccinesExpression of ADAM15 in rheumatoid synovium: up-regulation by vascular endothelial growth factor and possible implications for angiogenesisADAM-15 inhibits wound healing in human intestinal epithelial cell monolayersADAM15 gene structure and differential alternative exon use in human tissues.Inhibition of lung tumor colonization and cell migration with the disintegrin crotatroxin 2 isolated from the venom of Crotalus atrox.The mojastin mutant Moj-DM induces apoptosis of the human melanoma SK-Mel-28, but not the mutant Moj-NN nor the non-mutated recombinant Moj-WN.Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases.Recombinant rubistatin (r-Rub), an MVD disintegrin, inhibits cell migration and proliferation, and is a strong apoptotic inducer of the human melanoma cell line SK-Mel-28.Secreted and membrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration.Variability in melanoma metalloproteinase expression profilingHalting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain.DNA electrotransfer: its principles and an updated review of its therapeutic applications.Angiogenic and antiangiogenic gene therapy.Pancreatic Cancer Metastases Harbor Evidence of Polyclonality.An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization.Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy.Snake venom disintegrins and cell migration.Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma.The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.Gene therapy for patients with advanced solid tumors: a phase I study using gene electrotransfer to muscle with the integrin inhibitor plasmid AMEP.Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Helping Eve overcome ADAM: G-quadruplexes in the ADAM-15 promoter as new molecular targets for breast cancer therapeutics.Biological properties of melanoma and endothelial cells after plasmid AMEP gene electrotransfer depend on integrin quantity on cells.Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases.Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment.Critical role of ADAM15 in tumor progression: targeting multiple factors for metastasis promotion.ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis.Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib.Cross-drug resistance to sunitinib induced by doxorubicin in endothelial cells.Therapeutic levels of erythropoietin (EPO) achieved after gene electrotransfer to skin in mice.Variability of naked DNA expression after direct local injection: the influence of the injection speed.Tumor angiogenesis and anti-angiogenic gene therapy for cancer.
P2860
Q24602340-AA518EC5-AE0F-417F-959E-8DB0ED8263E2Q24812644-6E41BC59-4452-4D25-97DF-8C658288791AQ28281377-EFC743DC-E0EB-4D37-96A4-2FEFA667FCE4Q33302700-3F63694D-81F6-4D66-A727-E8A52225C2C1Q33326923-3B9628D1-6BF4-4E84-AEB8-EFBC590BB86DQ33558005-CFD2D73F-A1FE-404B-95CE-63EE80284CF3Q34022431-8927B656-5D39-4B8D-8EE0-9D0F09383FF1Q34109116-BA6E32FC-1787-4DBD-A085-4AC61C1B561FQ34203948-422DC614-8BE9-4B5B-B409-A8C8BBD94DAAQ34296399-63D8E245-25C4-4D8B-B0F6-A7B51D632400Q34428875-3F9A4BEE-E81F-4E8D-AE2F-7EE02ADEC80DQ34480626-1F8E7B3A-B0F4-46B3-B06B-FBF0496E2D6DQ35904419-3C493303-0995-4E6C-BD2F-63303765D6B9Q36288905-6D4B1E13-1E8E-4761-AC5B-9BF2C9A11754Q36311734-A8F2D4CB-7BB3-4715-BB62-51BDD84F89C3Q36804949-87861E44-27B3-49C1-A024-377619CAE926Q37028731-88349666-D89C-478C-9123-2CCE2C3E67DAQ37954274-BD2BE8D1-98BC-46D8-B890-A185C018AA3FQ38110273-BC55D651-469C-4A76-BA6C-C8BF3044739BQ38291507-A027C266-1472-450D-8A3B-36376F8210A9Q38691475-E6E64510-3EB5-41AF-BF80-BB9187CF1963Q38898489-DF4C6E41-8FA0-46D2-93CD-CE0C10D51EB6Q39045519-9444581C-037A-4401-8C2F-2E327C52942CQ39155558-EAA57614-1F85-4032-ADC6-17FDEA6CE186Q39162354-2587F3E6-F99B-4384-9501-7B2F396E825BQ39973056-BA95BDBC-3176-4BA8-8A8E-ACA146D9C39AQ40085257-8B64EF0C-7CA7-4CA0-B389-4A8F2A939FDCQ40712143-C5A47DEF-814A-47F1-95FE-A3D25F7E4B80Q41813347-A643363B-13D8-4D47-9619-FEEC543BAC94Q41921173-AA99E95A-81BA-478F-A763-B0AA1FB54FB0Q45858591-EA6DD8E2-56B6-4405-A206-E508B6A7D321Q45861363-7B8E8D34-37AA-4185-BB98-1425CFBC85CAQ55385227-9D338307-D38D-45DD-9601-4A387CDD1A35
P2860
Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@ast
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@en
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@nl
type
label
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@ast
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@en
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@nl
prefLabel
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@ast
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@en
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@nl
P2093
P1433
P1476
Evidence of antiangiogenic and ...... integrin domain of metargidin.
@en
P2093
Annick Thomaïdis
Chantal Legrand
Christophe Grenet
Claudine Soria
Dominique Martel-Renoir
Elisabeth Connault
Françoise Fauvel-Lafève
Jeannette Soria
P304
P356
10.1158/0008-5472.CAN-03-3272
P407
P577
2004-03-01T00:00:00Z